Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity Mar 27, 2024 08:30AM
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc. Jan 2, 2024 08:30AM
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc. Dec 12, 2023 08:30AM
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion Nov 16, 2023 08:30AM
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders Nov 15, 2023 12:00PM


Oct 18, 2023 08:34AM Odyssey Health (ODYY) Provides Update on Asset Purchase Agreement with Oragenics (OGEN)
Oct 18, 2023 08:30AM Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
Oct 5, 2023 06:30AM Oragenics (OGEN) to Acquire Odyssey Health’s (ODYY) Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Oct 5, 2023 06:30AM Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
Oct 4, 2023 08:30AM Odyssey Health Inc. Begins Trading on the OTCQB
Jan 12, 2023 08:30AM Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote
Dec 19, 2022 08:30AM Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023
Nov 23, 2022 08:30AM Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development
Nov 15, 2022 08:00AM Odyssey Health, Inc. Schedules Annual Meeting of Stockholders
Nov 3, 2022 08:30AM Odyssey Health Inc. Strengthens Commitment to Odyssey NeuroPharma Through Expansion of Executive Team
Nov 1, 2022 08:30AM Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device
Oct 11, 2022 08:30AM Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases
Oct 6, 2022 08:30AM Odyssey Health, Inc. Provides Recap on Concussion Drug Development
Sep 28, 2022 08:30AM Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug
Sep 13, 2022 08:00AM Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial, Cohort II
Aug 18, 2022 08:00AM Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Aug 10, 2022 08:00AM Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Aug 4, 2022 08:00AM Odyssey Health, Inc. Launches New Corporate Website
Jul 12, 2022 08:00AM Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Jun 29, 2022 08:30AM Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug
Jun 8, 2022 04:30PM RedChip Interviews Odyssey Health, Inc.’s CEO Michael Redmond
Jun 1, 2022 09:00AM Odyssey Health, Inc. Completes Safety Evaluation of Cohort I for Concussion Drug
May 5, 2022 08:30AM Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Apr 20, 2022 08:30AM Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Mar 31, 2022 08:30AM Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Feb 11, 2022 09:00AM NFL LEGEND BRETT FAVRE AND ODYSSEY HEALTH, INC. INVOLVED WITH HUMAN TRIALS OF FIRST DRUG TREATMENT FOR CONCUSSION
Jan 10, 2022 08:30AM Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation
Oct 19, 2021 10:03AM Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
Sep 22, 2021 08:39AM Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
Sep 1, 2021 08:30AM Odyssey Group International Approved to Start Human Trial to Treat Concussion        
Aug 30, 2021 08:00AM Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch
Aug 4, 2021 09:25AM Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial